Drug intelligence / Profile preview

mavacamten + activated charcoal + sorbitol

Development stage
Unknown
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral
01

Overview

This is a **combination product** containing three components: - **Mavacamten**, a small molecule that acts as a selective, allosteric, and reversible inhibitor of cardiac myosin, reducing hypercontractility of the heart muscle and used primarily in the management of symptomatic obstructive hypertrophic cardiomyopathy (HCM)[1][2][3][4][5]. - **Activated charcoal**, a form of carbon processed to have small, low-volume pores that increase surface area for adsorption; in medicine, it is used to treat some types of poisoning by binding to substances in the gastrointestinal tract and preventing their absorption. - **Sorbitol**, a sugar alcohol often used as a laxative or as a component in medicinal formulations; when combined with activated charcoal, it can hasten gastrointestinal transit and elimination of toxins. There is no evidence of this specific triple combination being an approved pharmaceutical product. If formulated, it could theoretically be used to facilitate the gastrointestinal elimination of mavacamten in overdose scenarios (by adsorption and hastening elimination), though this is speculative.

02

Targets

MYH7 (Cardiac beta-myosin heavy chain)

Beyond the preview

Go deeper on mavacamten + activated charcoal + sorbitol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mavacamten + activated charcoal + sorbitol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call